Reuters -- U.S. drug reviewers questioned a Genzyme Corp study meant to back wider use of the company’s Clolar leukemia drug, according to documents released on Friday ahead of an advisory panel review.
Reuters -- U.S. drug reviewers questioned a Genzyme Corp study meant to back wider use of the company’s Clolar leukemia drug, according to documents released on Friday ahead of an advisory panel review.
